AMPAR PET Imaging Links Ketamine to Rapid Antidepressant Response

Investigators used PET imaging to visualize cell-surface AMPA receptor (AMPAR) dynamics in people with treatment-resistant depression in relation to ketamine’s antidepressant effects, describing region-specific receptor changes associated with symptom improvement.

The analysis pooled data from three registered trials conducted in Japan and included 34 patients with treatment-resistant depression and 49 healthy control participants. Baseline PET data were analyzed for 34 patients, and matched pre/post PET data were analyzed for 31 participants in relation to symptom improvement. Investigators used a novel tracer, [11C]K-2 (study DOI), described as enabling direct visualization of cell-surface AMPAR in the living human brain. This design was presented as a way to compare baseline regional AMPAR patterns with shifts associated with ketamine administration over a two-week repeated-infusion protocol that included a double-blind ketamine-versus-placebo period.

At baseline, the authors reported a negative correlation between AMPAR density and illness severity in specific regions, along with region-specific abnormalities in AMPAR density in participants with treatment-resistant depression compared with healthy controls, rather than a uniform difference across the brain. In analyses linked to ketamine response, they described heterogeneous regional AMPAR changes rather than a single directional pattern. Some cortical areas were reported to show increases in AMPAR density in association with greater symptom improvement, while reductions in other regions were also associated with improvement, including in reward-related areas such as the habenula. Overall, the findings were framed as regionally variable AMPAR dynamics rather than brain-wide changes moving in lockstep.

The report also described an association between regional AMPAR shifts and improvements in depressive symptoms, presenting the imaging changes as correlates of symptomatic change rather than evidence of causation. In addition, the authors reported that baseline AMPAR distribution in some regions was associated with subsequent ketamine response, supporting the idea that AMPAR PET could be explored as a predictive biomarker for ketamine response. The source does not provide detailed adverse-event results in the summarized findings, although it does note safety-related considerations, including concerns about ketamine’s long-term safety and the possibility of unblinding due to adverse effects. In summary, the work links symptom improvement with region-specific AMPAR dynamics measured by PET imaging in patients receiving repeated ketamine infusions.

Key Takeaways:

• Investigators reported that [11C]K-2 PET enabled direct, in vivo assessment of cell-surface AMPAR in humans with treatment-resistant depression.
• Baseline AMPAR density was reported to correlate negatively with illness severity, and ketamine-associated symptom improvement was linked to regionally heterogeneous AMPAR changes, including cortical increases and reductions in regions such as the habenula.
• The authors proposed AMPAR PET as a candidate predictive biomarker for ketamine response, based in part on associations between pretreatment AMPAR distribution and later antidepressant response.